If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCropper (J) Regulatory News (CRPR)

Share Price Information for Cropper (J) (CRPR)

Share Price is delayed by 15 minutes
Get Live Data
380.00    30.00 (8.57%)
Bid:
370.00
Ask:
390.00
Spread: 20.00 (5.405%)
Market Cap: £36.31m
CRPR Live PriceLast checked at - London Stock Exchange

Intraday Cropper (J) Share Chart

Debt refinancing

Today 07:00

RNS Number : 6910K
Cropper(James) PLC
02 July 2026
 

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION PURSUANT TO ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

2 July 2026

 

James Cropper plc

("James Cropper", the "Company" or the "Group")

 

Debt refinancing

 

James Cropper plc (AIM: CRPR), the Advanced Materials and Paper & Packaging group, is pleased to announce the completion of a refinancing of its debt facilities. This refinancing provides the Group with a more flexible funding platform to support delivery of its medium-term strategic priorities.

 

The new arrangements improve the Group's cash flow and balance sheet flexibility through access to a new invoice discounting facility of up to £15m committed for at least three years, which provides flexible working capital funding to enable more efficient management of the Group's liquidity.

 

As part of the refinancing, the Group will make a part-repayment of £7.1m on its existing UK bank loan, funded from the Group's cash resources and the new invoice discounting facility, with the remaining balance repayable in reduced quarterly instalments through to March 2030.

 

In addition, the maturity of the Group's US bank loan has been extended by 12 months, with the final repayment of $3.2m deferred to December 2027, improving liquidity headroom during this period.

 

Alongside the debt refinancing, the Group has agreed to make a one-off contribution into its defined benefit pension schemes of £0.6m, with the previously agreed contribution schedule reduced by £0.35m in aggregate across the period to September 2027. In addition, the Group has agreed to bring forward the next triennial actuarial valuation of the pension schemes by 12 months to March 2027. 

 

Andrew Goody, Chief Financial Officer, said: "This refinancing builds on the significant progress we have made in strengthening the Group's balance sheet through improved operational performance and continued focus on cash and working capital management, with net debt at 28 March 2026 less than 1x adjusted EBITDA.

 

"The refinancing materially improves our liquidity and financial flexibility. By improving access to committed working capital funding and extending the maturity profile of our debt, the new arrangements provide greater headroom to support both operational requirements and strategic growth initiatives.

 

"Importantly, the refinancing allows us to deploy capital more efficiently, which we expect will allow the Group to reduce cash financing costs. I am grateful to our lending partners for their continued support and to HSBC Invoice Finance for helping deliver this important enhancement to our funding structure."

 

-END-

Enquiries

 

James Cropper plc

David Stirling, CEO

Andrew Goody, CFO

 

Tel: +44 (0)1539 722 002

Shore Capital - Nominated Adviser and Broker

Daniel Bush, David Coaten, Henry Willcocks, Lucy Bowden

 

Tel: +44 (0)207 408 4090

IFC Advisory - Financial PR

Graham Herring, Tim Metcalfe, Zach Cohen

Tel: +44 (0) 203 934 6630

james.cropper@investor-focus.co.uk

 

 

About James Cropper

 

James Cropper plc is globally recognised for its specialist capabilities in the design and manufacture of advanced materials and paper products. Operating through two principal businesses - Advanced Materials and Paper & Packaging - and built upon 180 years of innovation, the Group serves a diverse range of customers with high-performance solutions tailored to specialised applications.

 

The Advanced Materials business develops cutting-edge nonwoven materials and electrochemical coatings for sectors including aerospace, clean energy, and defence. The Paper & Packaging business offers premium creative papers and bespoke moulded fibre packaging together with leading recycled-fibre capabilities and products, supporting the transition to a circular economy.

 

Headquartered in Burneside (UK), with additional manufacturing sites in Crewe (UK), Launceston (UK), and Schenectady (USA), James Cropper leverages deep expertise in material science and longstanding partnerships with industry-leading businesses and brands to develop bespoke solutions that meet complex technical and aesthetic specifications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFFRDFILIIR
Date   Source Headline
10th Nov 20215:57 pmRNSRecord Date
9th Nov 20217:00 amRNSDirectorate Change
9th Nov 20217:00 amRNSHalf-year Report
4th Nov 20217:00 amRNSDirectorate Change
24th Sep 20211:44 pmRNSDirector/PDMR Shareholding
9th Sep 20215:35 pmRNSDirector/PDMR Shareholding
12th Aug 20217:00 amRNSGrant of Awards under Long Term Incentive Plan
5th Aug 20217:00 amRNSDirector/PDMR Shareholding
4th Aug 20217:00 amRNSDirector/PDMR Shareholding
28th Jul 202111:00 amRNSAGM Statement and Trading Update
27th Jul 202110:27 amRNSDirector/PDMR Shareholding
23rd Jul 20219:52 amRNSDirector/PDMR Shareholding
23rd Jul 20217:00 amRNSUpdate for visitors to the AGM
21st Jul 20217:00 amRNSDirector/PDMR Shareholding
6th Jul 20217:46 amRNSDirector/PDMR Shareholding
1st Jul 20212:30 pmRNSHolding(s) in Company
22nd Jun 20218:36 amRNSDirectorate Change
22nd Jun 20217:00 amRNSFinal Results
29th Mar 20217:00 amRNSDirector Dealing
25th Mar 20217:00 amRNSDirector/PDMR Shareholding
15th Mar 20219:31 amRNSDirector/PDMR Shareholding
8th Mar 20217:00 amRNSTrading Update
18th Jan 20217:00 amRNSAcquisition
18th Dec 202011:05 amRNSDirector/PDMR Shareholding
24th Nov 20207:00 amRNSDirector/PDMR Shareholding
17th Nov 20202:06 pmRNSSecond Price Monitoring Extn
17th Nov 20202:00 pmRNSPrice Monitoring Extension
10th Nov 20207:00 amRNSHalf-year Report
5th Aug 20207:00 amRNSGrant of Awards under Long Term Incentive Plan
31st Jul 20207:00 amRNSDirector/PDMR Shareholding
30th Jul 20209:41 amRNSResult of AGM
29th Jul 20207:00 amRNSAGM Statement and Trading Update
27th Jul 20201:47 pmRNSDirector/PDMR Shareholding
27th Jul 20209:00 amRNSDirectorate Change
23rd Jun 20207:00 amRNSFinal Results
1st May 20207:00 amRNSYear end and COVID 19 trading update
24th Mar 20203:57 pmRNSCOVID 19 update
20th Feb 20209:45 amRNSDirector Dealing
14th Feb 202010:13 amRNSDirector Dealing
30th Jan 20208:55 amRNSDirector/PDMR Shareholding
24th Jan 20204:30 pmRNSDirector/PDMR Shareholding
21st Jan 20202:00 pmRNSHolding(s) in Company
13th Jan 202011:05 amRNSDirector/PDMR Shareholding
17th Dec 201912:24 pmRNSDirector/PDMR Shareholding
13th Dec 20197:00 amRNSDirectors' Dealings
29th Nov 201910:42 amRNSDirector/PDMR Shareholding
19th Nov 20197:00 amRNSHalf-year Report
24th Sep 20197:00 amRNSDirector/PDMR Shareholding
17th Sep 201911:20 amRNSDirector/PDMR Shareholding
12th Aug 20197:00 amRNSDirectors' Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.